Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 1400

NCT06993792

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Orforglipron Dose 1 (Study GZP1)n/rn/rn/rn/r
Orforglipron Dose 2 (Study GZP1)n/rn/rn/rn/r
Orforglipron Dose 3 (Study GZP1)n/rn/rn/rn/r
Orforglipron Dose 4 (Study GZP1)n/rn/rn/rn/r
Placebo (Study GZP1)n/rn/rn/rn/r
Orforglipron Dose 1 (Study GZP2)n/rn/rn/rn/r
Orforglipron Dose 2 (Study GZP2)n/rn/rn/rn/r
Orforglipron Dose 3 (Study GZP2)n/rn/rn/rn/r
Orforglipron Dose 4 (Study GZP2)n/rn/rn/rn/r
Placebo (Study GZP2)n/rn/rn/rn/r

Not shown

  • Orforglipron Dose 1 (Study GZP1): endpoint not reported
  • Orforglipron Dose 2 (Study GZP1): endpoint not reported
  • Orforglipron Dose 3 (Study GZP1): endpoint not reported
  • Orforglipron Dose 4 (Study GZP1): endpoint not reported
  • Placebo (Study GZP1): endpoint not reported
  • Orforglipron Dose 1 (Study GZP2): endpoint not reported
  • Orforglipron Dose 2 (Study GZP2): endpoint not reported
  • Orforglipron Dose 3 (Study GZP2): endpoint not reported
  • Orforglipron Dose 4 (Study GZP2): endpoint not reported
  • Placebo (Study GZP2): endpoint not reported